Sander Deventer, Amsterdam Molecular Therapeutics’s (AMT) chief scientific officer and co-founder of the company, has been named CEO on an interim basis.
The company has said that the supervisory board will begin a search for a new CEO immediately.
Ferdinand Verdonck, chairman of the supervisory board at AMT, said: “Under Ronald’s leadership the company has delivered outstanding results for which we are very grateful. We look forward to continuing the execution of the company strategy by building on this strong foundation.”